Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
267
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

ARCA Biopharma, Inc.

Collaborators